You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

CLINICAL TRIALS PROFILE FOR GLATOPA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for GLATOPA

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03982212 ↗	A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors	Recruiting	University of Kansas Medical Center	Phase 1	2019-07-26	The investigator believes that injecting Copaxone into tumors will help participants immune system fight cancer. This has been studied in mice and has shown encouraging results. Copaxone is a safe medication currently used to treat Multiple Sclerosis (MS) and has very few side effects. To be considered for this trial a tumor must be easy to be injected and must be at least the size of a pea. Participants will be closely monitored for any side effects. Tissue from before surgery will be compared to tissue after the treatment and surgery to be checked for immune response and anti-tumor effects.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for GLATOPA

Condition Name

Chart
Table

Condition Name for GLATOPA
Intervention	Trials
Basal Cell Carcinoma	1
Cutaneous Squamous Cell Carcinoma	1
Percutaneous Tumor	1
Squamous Cell Carcinoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for GLATOPA
Intervention	Trials
Carcinoma, Squamous Cell	1
Carcinoma, Basal Cell	1
Carcinoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for GLATOPA

Trials by Country

Map
Table

Trials by Country for GLATOPA
Location	Trials
United States	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for GLATOPA
Location	Trials
Kansas	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for GLATOPA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for GLATOPA
Clinical Trial Phase	Trials
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for GLATOPA
Clinical Trial Phase	Trials
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GLATOPA

Sponsor Name

Chart
Table

Sponsor Name for GLATOPA
Sponsor	Trials
University of Kansas Medical Center	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for GLATOPA
Sponsor	Trials
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.